Wealth Enhancement Advisory Services LLC grew its position in CME Group Inc. (NASDAQ:CME - Free Report) by 4.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,452 shares of the financial services provider's stock after purchasing an additional 2,686 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in CME Group were worth $14,968,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank acquired a new stake in shares of CME Group in the 4th quarter valued at $1,107,389,000. Price T Rowe Associates Inc. MD raised its position in CME Group by 89.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,280,785 shares of the financial services provider's stock worth $1,923,047,000 after purchasing an additional 3,921,278 shares during the last quarter. Raymond James Financial Inc. bought a new position in CME Group in the 4th quarter valued at $871,063,000. Capital Wealth Planning LLC increased its stake in shares of CME Group by 69.2% in the 4th quarter. Capital Wealth Planning LLC now owns 2,435,823 shares of the financial services provider's stock valued at $565,671,000 after buying an additional 996,498 shares during the period. Finally, Egerton Capital UK LLP acquired a new stake in CME Group in the fourth quarter worth about $223,967,000. Institutional investors own 87.75% of the company's stock.
CME Group Price Performance
Shares of NASDAQ CME traded down $8.40 during mid-day trading on Tuesday, reaching $282.31. 2,699,116 shares of the company were exchanged, compared to its average volume of 2,188,841. The stock has a market capitalization of $101.73 billion, a PE ratio of 29.19, a PEG ratio of 6.76 and a beta of 0.45. The company has a quick ratio of 1.02, a current ratio of 1.01 and a debt-to-equity ratio of 0.10. CME Group Inc. has a 52 week low of $190.70 and a 52 week high of $290.79. The company's 50 day moving average price is $270.54 and its 200 day moving average price is $251.90.
CME Group (NASDAQ:CME - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The financial services provider reported $2.80 earnings per share for the quarter, topping analysts' consensus estimates of $2.61 by $0.19. CME Group had a net margin of 57.52% and a return on equity of 13.62%. The firm had revenue of $1.64 billion during the quarter, compared to analyst estimates of $1.56 billion. During the same period in the previous year, the business posted $2.50 EPS. The business's quarterly revenue was up 10.4% on a year-over-year basis. Sell-side analysts forecast that CME Group Inc. will post 10.49 earnings per share for the current fiscal year.
CME Group Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Monday, June 9th will be given a dividend of $1.25 per share. The ex-dividend date is Monday, June 9th. This represents a $5.00 annualized dividend and a yield of 1.77%. CME Group's payout ratio is 50.30%.
Analysts Set New Price Targets
Several brokerages recently commented on CME. Raymond James raised CME Group from a "market perform" rating to an "outperform" rating and set a $287.00 price objective on the stock in a research note on Monday, March 10th. JPMorgan Chase & Co. cut their price objective on CME Group from $223.00 to $211.00 and set an "underweight" rating on the stock in a report on Thursday, April 24th. Piper Sandler boosted their price objective on CME Group from $275.00 to $283.00 and gave the company an "overweight" rating in a research report on Tuesday, April 8th. UBS Group raised their target price on shares of CME Group from $290.00 to $305.00 and gave the stock a "buy" rating in a report on Friday, April 25th. Finally, Oppenheimer upped their price target on shares of CME Group from $269.00 to $279.00 and gave the company an "outperform" rating in a report on Friday, April 11th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $256.80.
Read Our Latest Stock Analysis on CME
Insider Activity
In other news, Director Phyllis M. Lockett sold 1,060 shares of CME Group stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $277.88, for a total value of $294,552.80. Following the sale, the director now directly owns 3,108 shares in the company, valued at approximately $863,651.04. This trade represents a 25.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Larry G. Gerdes sold 2,000 shares of the business's stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $264.10, for a total value of $528,200.00. Following the transaction, the director now directly owns 38,651 shares in the company, valued at $10,207,729.10. This trade represents a 4.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,900 shares of company stock valued at $6,147,935. 0.30% of the stock is currently owned by insiders.
CME Group Profile
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Read More

Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report